ISRU Propellant Selection for Space Exploration Vehicles

Autor: Timothy T. Chen, Douglas G. Thorpe

Publikováno v: 49th AIAA/ASME/SAE/ASEE Joint Propulsion Conference.

Chemical propulsion remains the only viable solution as technically matured technology for the near term human space transportation to Lunar and Mars. Current mode of space travel requires us to "take everything we will need", including propellant fo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c75c99be23e4ae9d6bed5ea3a406a3ae
https://doi.org/10.2514/6.2013-3804

Need for Technology Maturity of Any Advanced Capability to Achieve Better Life Cycle Cost

Autor: Russel E. Rhodes, Daniel J. H. Levack, Timothy T. Chen, John W. Robinson

Publikováno v: 45th AIAA/ASME/SAE/ASEE Joint Propulsion Conference & Exhibit.

Programs such as space transportation systems are developed and deployed only rarely, and they have long development schedules and large development and life cycle costs (LCC). They have not historically had their LCC predicted well and have only had

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::56bbb0c3ddfa6b798b9e84cb257eb1b2
https://doi.org/10.2514/6.2009-5347

Role of elective brain irradiation during combined chemoradiotherapy for limited disease non-small cell lung cancer

Autor: H.Thomas Barkley, Valdivieso M, Timothy T. Chen, Hari M. Dhingra, Peter Farha, Delia F. Chiuten, Calvin L. Dixon, Daniel J. Booser, Gary Spitzer, William K. Murphy, Theera Umsawasdi, Carr Dt

Publikováno v: Journal of Neuro-Oncology. 2:253-259

We have studied the clinical impact of elective brain irradiation (EBI) in patients with locally advanced, non-small cell lung cancer (LA-NSC). All patients received combination chemotherapy (cyclophosphamide + doxorubicin (Adriamycin) + cisplatin =

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::897e213cc1032ae21dbd0523d2817487
https://doi.org/10.1007/bf00253278

Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.

Autor: Hoff FW; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX., Blum WG; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA., Huang Y; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Welkie RL; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Swords RT; Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Traer E; Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Stein EM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Lin TL; Department of Internal Medicine, The University of Kansas Medical Center, Kansas City, KS., Archer KJ; Division of Biostatistics, The Ohio State University, Columbus, OH., Patel PA; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX., Collins RH; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX., Baer MR; Department of Medicine, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD., Duong VH; Department of Medicine, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD., Arellano ML; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA., Stock W; Department of Medicine, The University of Chicago, Chicago, IL., Odenike O; Department of Medicine, The University of Chicago, Chicago, IL., Redner RL; Department of Medicine, University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA., Kovacsovics T; Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, UT., Deininger MW; Department of Internal Medicine, Versiti Blood Research Institute and Medical College of Wisconsin, Milwaukee, WI., Zeidner JF; Division of Hematology, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC., Olin RL; Department of Medicine, University of California, San Francisco, San Francisco, CA., Smith CC; Department of Medicine, University of California, San Francisco, San Francisco, CA., Foran JM; Department of Internal Medicine, Mayo Clinic, Jacksonville, FL., Schiller GJ; Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA., Curran EK; Deparrtment of Internal Medicine, University of Cincinnati, Cincinnati, OH., Koenig KL; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Heerema NA; Department of Pathology, The Ohio State University, Columbus, OH., Chen T; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Martycz M; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Stefanos M; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Marcus SG; Leukemia & Lymphoma Society, Rye Brook, NY., Rosenberg L; Leukemia & Lymphoma Society, Rye Brook, NY., Druker BJ; Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Levine RL; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Burd A; Leukemia & Lymphoma Society, Rye Brook, NY., Yocum AO; Leukemia & Lymphoma Society, Rye Brook, NY., Borate UM; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Mims AS; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Byrd JC; Deparrtment of Internal Medicine, University of Cincinnati, Cincinnati, OH., Madanat YF; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.

Publikováno v: Blood advances [Blood Adv] 2024 Oct 22; Vol. 8 (20), pp. 5297-5305.

Factors associated with electroconvulsive therapy treatment for adults with serious psychiatric conditions in Australia.

Autor: Chen T; University of New South Wales, Sydney, NSW, Australia., Loo C; Discipline of Psychiatry, School of Clinical Medicine, University of New South Wales, Sydney, NSW, Australia.; Black Dog Institute, Randwick, NSW, Australia., Salvador-Carulla L; Health Research Institute, University of Canberra, Canberra, ACT, Australia., Jorm LR; Centre for Big Data Research in Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia., Srasuebkul P; Department of Developmental Disability Neuropsychiatry, Discipline of Psychiatry and Mental Health, University of New South Wales, Sydney, NSW, Australia., Sara G; Discipline of Psychiatry, School of Clinical Medicine, University of New South Wales, Sydney, NSW, Australia.; NSW Ministry of Health, St Leonards, NSW, Australia., Quiroz JC; Centre for Big Data Research in Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia., Gallego B; Centre for Big Data Research in Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.

Publikováno v: The Australian and New Zealand journal of psychiatry [Aust N Z J Psychiatry] 2024 Sep; Vol. 58 (9), pp. 809-820. Date of Electronic Publication: 2024 Jul 27.